On Wednesday, April 21, Tureci told CNBC's Kelly Evans on "The Exchange" that scientists expect vaccine-induced immunity against the virus will decrease over time.
"We see indications for this also in the natural immune response against SARS-CoV-2," she said referring to the virus that causes COVID-19. "We see this waning of immune responses in people who were just infected and therefore [it's] also expected with the vaccines."
Bourla said earlier this month that people will likely need a booster shot – or third dose – of the COVID-19 vaccine within 12 months of getting fully vaccinated. He also said people will possibly need to get an additional shot each year. (Related: Pfizer's vaccine studies are based on FRAUD and put lives in danger, warns former Pfizer vice president.)
"A likely scenario is that there will be likely a need for a third dose, somewhere between six and 12 months and then from there, there will be an annual revaccination, but all of that needs to be confirmed. And again, the variants will play a key role," he told CNBC's Bertha Coombs during an event with CVS Health.
"It is extremely important to suppress the pool of people that can be susceptible to the virus," Bourla added.
Executives of Big Pharma companies have been echoing each other's sentiments, in regards to their coronavirus vaccines.
Johnson & Johnson CEO Alex Gorsky started using the narrative in February when he told CNBC that people may need to get vaccinated against COVID-19 annually, just like seasonal flu shots.
Moderna CEO Stephane Bancel also said in a recent interview on CNBC's "Squawk Box" that annual COVID vaccine boosters will be commonplace going forward, saying the coronavirus "is not going away" and it's "not leaving the planet."
Ironically, Pfizer-BioNTech and Moderna began talking about booster shots while boasting the high efficacy rate of their COVID-19 shots. Pfizer claimed earlier this month that the COVID-19 vaccine it developed with BioNTech is more than 91 percent effective at protecting against the virus and more than 95 percent effective against severe disease up to six months after the second dose.
Moderna also announced this month that its COVID-19 vaccine was more than 90 percent effective at protecting against COVID up to six months after the second dose. It was more than 95 percent effective against severe diseases within the same period.
Should Americans require booster shots, the government will likely need to make arrangements with Big Pharma companies and make plans for vaccine distribution.
Andy Slavitt, senior advisor to President Joe Biden's COVID response team, said on Friday, April 23, that the White House is preparing for the potential need for COVID-19 vaccine booster shots.
"I can assure you that when we do our planning, when the president orders purchases of additional vaccines as he has done and when we focus on all the production expansion opportunities that we talk about in here we very much have scenarios like that in mind," he said at a White House press briefing.
David Kessler, the Biden administration's COVID response chief science officer, said last week that Americans should expect to receive booster shots to protect against coronavirus variants. He told lawmakers that currently authorized vaccines are highly protective but noted new variants could challenge the effectiveness of the shots.
"We don't know everything at this moment. We are studying the durability of the antibody response," he told the House Select Subcommittee on the Coronavirus Crisis.
"It seems strong, but there is some waning of that, and no doubt the variants challenge ... they make these vaccines work harder. So I think for planning purposes, planning purposes only, I think we should expect that we may have to boost."
As the government plans, Big Pharma prepares.
"I want to make sure there are boost vaccines available in the fall so that we protect people as we go into the next fall and winter season in the U.S.," said Moderna's Bancel.
Last month, the National Institutes of Health began testing a variety of offerings from Moderna to use as a third shot designed to boost immunity protection as concern grows about emerging variants – including the one first discovered in South Africa, also known as the B.1.351 variant. That variant has been shown to reduce the effectiveness of existing COVID vaccines. (Related: New docs: NIH owns half of Moderna vaccine.)
The Food and Drug Administration's approach to authorizing modified COVID vaccines is similar to that of annual flu vaccines, meaning they could be cleared for emergency use without lengthy clinical trials.
According to Bancel, Moderna hopes to submit data to regulators within a few months. "Our goal is to work really hard to get this ready before the fall," he reiterated.
"I anticipate in the next year or so, we're going to see a lot of variants. But as more and more people get vaccinated or naturally infected, the pace of the variant is going to slow down and the virus is going to stabilize like you see with flu," he said.
Moderna has an ambitious goal of creating a two-in-one vaccine that protects against seasonal flu and COVID-19. The company announced in September last year its intentions to make a combined vaccine.
"What we're trying to do at Moderna actually is to get a flu vaccine in the clinic this year and then combine our flu vaccine to our COVID vaccine so you only have to get one boost at your local CVS store every year that would protect you to the variant of concern against COVID and the seasonal flu strain," Bancel said. "We believe we can get to a high efficacy flu vaccine."
Follow Immunization.news for more news and information related to coronavirus vaccines.